Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development : memorandum from a joint WHO/NIAID meeting
Outros títulos
Etat d' avancement des vaccins contre le virus respiratoire syncytial (RSV) et le virus parainfluenza type 3 (PIV3) : mémorandum d' une réunion conjointe OMS/NIAIDCitação
(1997). Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development : memorandum from a joint WHO/NIAID meeting. http://www.who.int/iris/handle/10665/54931
Relação
Bulletin of the World Health Organization 1997 ; 75(4) : 307-313
Descrição
In English with summary in FrenchBased on the report of a joint WHO/National Institute of Allergy and Infectious Diseases meeting, held in Bethesda, MD, USA, on 30 September to 1 October 1996
Colecções
Metadados
Mostrar o registo completo do documentoDocumentos relacionados
Mostrar documentos relacionados por título, autor, criador e tema.
-
WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines
(WHO/IVB/17.11, 2017) -
Circulation of Respiratory Syncytial Virus in Morocco during 2014-2016: Findings from a sentinel-based virological surveillance system for influenza
(2016-07)Respiratory syncytial virus [RSV] is a leading cause of mortality and morbidity in young infants, little was known on its circulation types and patterns in Morocco. We conducted a prospective study using sentinel-based influenza surveillance to detect RSV by real time PCR in patients with acute respiratory infections, enrolled during two seasons [2014/15, 2015/16]. During September 2014-April 2016, we obtained 1450 specimens, of which 267 [18.4%] tested positive for RSV. The proportion of positive RSV infection was higher in patients hospitalized ...
